In the future, there might be a role for pharmacological adjuncts with inhibitory effects on iNOS in the treatment of IP conditions for patients with obesity or high-fat dietary habit under refractory scenarios or suboptimal pain control using routine analgesic regimens. Here, NOS2 is linked to Obesity.